TrialClinical and translational medicine2026
Rezvilutamide plus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer patients after progression on abiraterone: A multi-centre, open-label, phase II trial.
Zhenhua Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.